Lecanemab (Swedish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lecanemab" in Swedish language version.

refsWebsite

Global rank Swedish rank

2^nd place

14^th place

447^th place

1,667^th place

4^th place

17^th place

low place

low place

5^th place

9^th place

2,374^th place

1,630^th place

485^th place

527^th place

low place

low place

alzforum.org

”Leqembi | ALZFORUM” (på engelska). www.alzforum.org. https://www.alzforum.org/therapeutics/leqembi. Läst 16 februari 2024.
”Leqembi | ALZFORUM” (på engelska). www.alzforum.org. https://www.alzforum.org/therapeutics/leqembi. Läst 16 februari 2024.

doi.org

dx.doi.org

”Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease”. Brain Communications 5 (3): sid. fcad175. 2 maj 2023. doi:10.1093/braincomms/fcad175. PMID 37389302.
van Dyck, Christopher H.; Swanson, Chad J.; Aisen, Paul; Bateman, Randall J.; Chen, Christopher; Gee, Michelle (2023-01-05). ”Lecanemab in Early Alzheimer’s Disease” (på engelska). New England Journal of Medicine 388 (1): sid. 9–21. doi:10.1056/NEJMoa2212948. ISSN 0028-4793. http://www.nejm.org/doi/10.1056/NEJMoa2212948. Läst 16 februari 2024.
Liu, Kathy Y; Villain, Nicolas; Ayton, Scott; Ackley, Sarah F; Planche, Vincent; Howard, Robert (2023-05-02). ”Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease” (på engelska). Brain Communications 5 (3). doi:10.1093/braincomms/fcad175. ISSN 2632-1297. PMID 37389302. PMC: PMC10306158. https://academic.oup.com/braincomms/article/doi/10.1093/braincomms/fcad175/7188710. Läst 16 februari 2024.
Tucker, Stina; Möller, Christer; Tegerstedt, Karin; Lord, Anna; Laudon, Hanna; Sjödahl, Johan (2014-11-21). ”The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice”. Journal of Alzheimer's Disease 43 (2): sid. 575–588. doi:10.3233/JAD-140741. https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-140741. Läst 16 februari 2024.

fda.gov

fda.gov

Office of the Commissioner (6 januari 2023). ”FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment” (på engelska). FDA. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment. Läst 16 februari 2024.
Office of the Commissioner (7 juli 2023). ”FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval” (på engelska). FDA. https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Läst 16 februari 2024.

accessdata.fda.gov

”Drug Approval Package: Leqembi”. U.S. Food and Drug Administration (FDA). 6 februari 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761269Orig1s000TOC.cfm.

medra.org

Tucker, Stina; Möller, Christer; Tegerstedt, Karin; Lord, Anna; Laudon, Hanna; Sjödahl, Johan (2014-11-21). ”The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice”. Journal of Alzheimer's Disease 43 (2): sid. 575–588. doi:10.3233/JAD-140741. https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-140741. Läst 16 februari 2024.

nejm.org

van Dyck, Christopher H.; Swanson, Chad J.; Aisen, Paul; Bateman, Randall J.; Chen, Christopher; Gee, Michelle (2023-01-05). ”Lecanemab in Early Alzheimer’s Disease” (på engelska). New England Journal of Medicine 388 (1): sid. 9–21. doi:10.1056/NEJMoa2212948. ISSN 0028-4793. http://www.nejm.org/doi/10.1056/NEJMoa2212948. Läst 16 februari 2024.

nih.gov

ncbi.nlm.nih.gov

”Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease”. Brain Communications 5 (3): sid. fcad175. 2 maj 2023. doi:10.1093/braincomms/fcad175. PMID 37389302.
Liu, Kathy Y; Villain, Nicolas; Ayton, Scott; Ackley, Sarah F; Planche, Vincent; Howard, Robert (2023-05-02). ”Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease” (på engelska). Brain Communications 5 (3). doi:10.1093/braincomms/fcad175. ISSN 2632-1297. PMID 37389302. PMC: PMC10306158. https://academic.oup.com/braincomms/article/doi/10.1093/braincomms/fcad175/7188710. Läst 16 februari 2024.

dailymed.nlm.nih.gov

”DailyMed - LEQEMBI- lecanemab injection, solution”. dailymed.nlm.nih.gov. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975. Läst 16 februari 2024.

oup.com

academic.oup.com

Liu, Kathy Y; Villain, Nicolas; Ayton, Scott; Ackley, Sarah F; Planche, Vincent; Howard, Robert (2023-05-02). ”Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease” (på engelska). Brain Communications 5 (3). doi:10.1093/braincomms/fcad175. ISSN 2632-1297. PMID 37389302. PMC: PMC10306158. https://academic.oup.com/braincomms/article/doi/10.1093/braincomms/fcad175/7188710. Läst 16 februari 2024.

worldcat.org

van Dyck, Christopher H.; Swanson, Chad J.; Aisen, Paul; Bateman, Randall J.; Chen, Christopher; Gee, Michelle (2023-01-05). ”Lecanemab in Early Alzheimer’s Disease” (på engelska). New England Journal of Medicine 388 (1): sid. 9–21. doi:10.1056/NEJMoa2212948. ISSN 0028-4793. http://www.nejm.org/doi/10.1056/NEJMoa2212948. Läst 16 februari 2024.
Liu, Kathy Y; Villain, Nicolas; Ayton, Scott; Ackley, Sarah F; Planche, Vincent; Howard, Robert (2023-05-02). ”Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease” (på engelska). Brain Communications 5 (3). doi:10.1093/braincomms/fcad175. ISSN 2632-1297. PMID 37389302. PMC: PMC10306158. https://academic.oup.com/braincomms/article/doi/10.1093/braincomms/fcad175/7188710. Läst 16 februari 2024.